Myelodysplastic Syndrome Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Myelodysplastic Syndrome stocks.

Myelodysplastic Syndrome Stocks Recent News

Date Stock Title
Nov 1 ALXO ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
Nov 1 ARGX argenx downgraded at Baird as shares get pricey
Nov 1 SYRS Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ...
Nov 1 LGND Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
Nov 1 ARGX argenx SE (ARGNF) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Challenges
Nov 1 ACLX Arcellx (ACLX) Surged in Q3. Here’s Why
Oct 31 ARGX Here’s Why You Should Hold Argenx SE (ARGX)
Oct 31 SYRS Syros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call Transcript
Oct 31 ARGX Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat
Oct 31 ARGX argenx SE (ARGX) Q3 2024 Earnings Call Transcript
Oct 31 ARGX argenx SE 2024 Q3 - Results - Earnings Call Presentation
Oct 31 MRUS Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates
Oct 31 MRUS Merus GAAP EPS of -$1.46, revenue of $11.77M
Oct 31 MRUS Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
Oct 31 SYRS Syros Pharmaceuticals GAAP EPS of -$0.16 beats by $0.52
Oct 31 SYRS Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
Oct 31 ARGX Argenx SE reports Q3 results
Oct 31 ARGX argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
Oct 30 SYRS Syros Pharmaceuticals Q3 2024 Earnings Preview
Oct 30 ARGX Argenx SE Q3 2024 Earnings Preview
Myelodysplastic Syndrome

Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells. Early on, there are typically no symptoms. Later symptoms may include feeling tired, shortness of breath, easy bleeding, or frequent infections. Some types may develop into acute myeloid leukemia.Risk factors include previous chemotherapy or radiation therapy, exposure to certain chemicals such as tobacco smoke, pesticides, and benzene, and exposure to heavy metals such as mercury or lead. Problems with blood cell formation result in some combination of low red blood cells, low platelets, and low white blood cells. Some types have an increase in immature blood cells, called blasts, in the bone marrow or blood. The types of MDS are based on specific changes in the blood cells and bone marrow.Treatments may include supportive care, drug therapy, and stem cell transplantation. Supportive care may include blood transfusions, medications to increase the making of red blood cells, and antibiotics. Drug therapy may include the medication lenalidomide, antithymocyte globulin, and azacitidine. Certain people can be cured with chemotherapy followed by a stem-cell transplant from a donor.About seven per 100,000 people are affected with about four per 100,000 people newly acquiring the condition each year. The typical age of onset is 70 years. The outlook depends on the type of cells affected, the number of blasts in the bone marrow or blood, and the changes present in the chromosomes of the affected cells. The typical survival time following diagnosis is 2.5 years. The conditions were first recognized in the early 1900s. The current name came into use in 1976.

Browse All Tags